Drug Monograph

Drug/Drug Class: **Kevzara® (sarilumab) solution for injection/TIMs**
Prepared for: MO HealthNet
Prepared by: Conduent

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Kevzara® is now available in single-dose prefilled pens containing either 150 mg sarilumab per 1.14 ml or 200 mg sarilumab per 1.14 ml. It is supplied in a pack containing 2 prefilled pens.
Manufacturer:	Sanofi-Aventis U.S. LLC, Bridgewater, NJ 08807 and Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591.
Indications:	Kevzara® is indicated for treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs.
Costs:	$1,573.17 per pen of each strength of Kevzara®. Maximum Allowable Cost
Summary of Findings:	This drug is being considered for inclusion in the state specific Preferred Drug List (PDL).
Status Recommendation:	☐ Prior Authorization (PA) Required ☐ Open Access ☐ Fiscal Edit ☒ PDL
Type of PA Criteria:	☐ Increased Risk of ADE ☒ Non-preferred ☐ Appropriate Indications ☐ No PA Required

Prepared By: Luke Boehmer PharmD
Date: August 20, 2018

© 2018 Conduent Business Services, LLC All Rights Reserved.